Angiotensin-converting enzyme inhibitors (ACEIs) are largely employed for treating patients with left ventricular dysfunction (LVD), but their efficacy may be negatively affected by concomitant administration of acetylsalicylic acid (ASA), with some difference among the different compounds.
The interaction between ASA and the two ACEIs zofenopril and ramipril may result in a different impact on survival of cardiac patients, due to differences in the pharmacological properties of the two ACEIs.
This phase IIIb, randomized, double-blind, parallel-group, multicenter, European study compared the safety and efficacy of zofenopril (60 mg/day) and ramipril (10 mg/day) plus ASA (100 mg/day), in 771 patients with LVD (clinical signs of heart failure or a left ventricular ejection fraction <45%) following acute myocardial infarction (AMI). The primary study end point was 1-year combined occurrence of death or hospitalization for cardiovascular causes.
In the intention-to-treat population, the primary outcome was significantly reduced by zofenopril (n = 365) vs ramipril (n = 351) (odds ratio [OR]: 0.70, and 95% confidence interval [CI]: 0.51-0.96; P = 0.028) as a result of a decrease in cardiovascular hospitalization (OR: 0.64,95% CI: 0.46-0.88; P = 0.006). Mortality rate was not significantly different between the 2 treatments (OR: 1.51, 95% CI: 0.70-3.27; P = 0.293). Blood pressure values did not significantly change during the 1-year follow-up. N-terminal pro-brain natriuretic peptide levels were progressively reduced during the study, with no statistically significant between-treatment differences. Proportion of patients with deterioration of renal function during the study was similar between the 2 groups. Drug safety profile was comparable between treatments.
In patients with LVD following AMI, the efficacy of zofenopril associated with ASA was superior to that of ramipril plus ASA, indicating some important clinical implications for the future use of ACEIs in patients with LVD or overt heart failure. Clin. Cardiol. 2012 doi: 10.1002/clc.22017
Trial registration: EudraCT Number: 2004-001150-88 (www.clinicaltrialsregister.eu); Italian Ministry of Health Code: GUID OTT_III_2004_001 (https://oss-sper-clin.agenziafarmaco.it).
This work was financially supported by Menarini International Operations Luxembourg S.A., Laboratori Guidotti S.p.A., and Istituto Lusofarmaco d'Italia S.p.A. through an unconditional and unrestricted grant. The funding source did not influence or comment on planned methods, protocol, data analysis, or the draft report.
Claudio Borghi, MD, is a shareholder at Abbott USA and BMS USA, and a consultant at Boheringer Ingelheim and Menarini International.
The authors have no other funding, financial relationships, or conflicts of interest to disclose.